# A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa

> **NCT00211068** · — · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 124 (actual)

## Conditions studied

- Pure Red-cell Aplasia

## Interventions

- **DRUG:** No intervention

## Key facts

- **NCT ID:** NCT00211068
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** 2006-03
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2013-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00211068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00211068, "A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00211068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*